Apr 17, 2014
Horizon Pharma Announces the Appointment of H. Thomas Watkins to Its Board of Directors
Additionally, Jean-Francois Formela, M.D. has resigned from the Horizon board of directors.
Bad news for GlaxoSmithKline's darapladib, a drug key to Human Genome Sciences buyout
GlaxoSmithKline this weekend illustrated disappointing results of a late-stage trial for heart drug darapladib, one of the three major assets the British pharma company scooped up in its $3 billion acquisition of Rockville's Human Genome Sciences two years ago.
ComplianceOnline Seminar on Statistical Analysis for Product Development Comes to Wisconsin
ComplianceOnline, the leading GRC advisory network, and well known regulatory affairs expert Steven Walfish are teaming up again to conduct the best-selling statistical analysis for product development seminar - this time in Madison on April 24 and 25, 2014.
WellDoc Names Biotech Veteran as President
WellDoc , developers of the first FDA-cleared, mobile prescription therapy, BlueStar TM, announced today that Kevin P. McRaith has joined the Company as President.
Splicing Human Genome Sciences: The post-mortem on a top Md. biotech
Alongside MedImmune , Rockville-based HGS was among the most bragged-about companies in one of the state's most coveted industries.